Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2026 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
With the release of two new classes of antiretrovirals last fall, most care providers needed to quickly get back on the learning curve to master both drugs simultaneously. Fortunately, the new integrase inhibitor raltegravir (Isentress) has one standard dosage for all adults: one pill twice a day with or without food. It has no drug interactions and should work in any patient with HIV. However, it takes a little more study to use the other newly approved drug, maraviroc (Selzentry). When it was discovered that people are essentially resistant to HIV if they lack the CCR5 receptor on the surface of their CD4 cells, the hunt was on to find a CCR blocker. Maraviroc is the first of this class. But only about 70% to 80% of people with HIV have an R5 virus that uses CCR5 to gain access to the CD4 cell. About 2% to 5% have an X4 virus that uses another receptor, CXCR4. The remaining 20% to 30% have a virus population that is a mixture of R5 and X4. The first step in using maraviroc is to test to see if a patient has R5 virus. This test is currently available through only one laboratory. It takes two to three weeks to get results and requires a viral load of at least 1,000. The test is also expensive, but at the moment it seems to be covered by insurance. Next, the dosage may need to be raised or lower based on what other drugs the patient is taking, since maraviroc is processed through a common liver pathway called CYP 3A4. This is the pathway used by most protease inhibitors and blocked by ritonavir. Hence, the maraviroc dosage is cut in half when used in combination with a ritonavir-boosted protease inhibitor. Alternatively maraviroc must be double when used with efavirenz, which up-regulates CYP 3A4 activity. Then there are exceptions like nevirapine or boosted tipranovir, both of which cause no change in maraviroc levels. And when both a boosted PI and efavirenz are used, the boosted-PI affect wins and the dosage is halved. Confused and concerned? Don't be. The maraviroc prescribing literature has a clear chart to follow. But don't forget to review the maraviroc dosage whenever changes are made in a treatment regimen. At least it is as easy to take as raltegravir: one pill twice a day with or without food. Bowers is an HIV specialist and board-certified physician in family practice, and he is a senior partner with Pacific Oaks Medical Group, one of the largest U.S. practices devoted to HIV care, in Beverly Hills, Calif.
From our Sponsors
Most Popular
“So much life to live”: Eric Nieves on thriving with HIV
September 03 2025 11:37 AM
Amazing People of 2025: Javier Muñoz
October 17 2025 7:35 PM
It’s National PrEP Day! Learn the latest about HIV prevention
October 10 2025 9:00 AM
“I am the steward of my ship”: John Gibson rewrites his HIV narrative
September 16 2025 2:56 PM
Plus: Featured Video
Latest Stories
HIV-positive men stage 'Kiss-In' protest at U.S.-Mexico border
December 01 2025 12:56 PM
What the AIDS crisis stole from Black gay men
December 01 2025 6:00 AM
The Talk: Owning your voice
August 25 2025 8:16 PM
The lab coat just got queer
August 21 2025 10:00 AM
Messenger RNA could be the key to an HIV vaccine — but government cuts pose a threat
August 20 2025 8:02 AM
The Talk: Beyond the exam room
August 13 2025 3:15 PM
The Talk: Navigating your treatment
August 01 2025 6:02 PM
The Talk: Starting the conversation
July 25 2025 4:47 PM
Thanks to U=U, HIV-positive people can live long, happy, healthy lives
July 25 2025 2:37 PM
How the Black AIDS Institute continues to fill in the gaps
July 25 2025 1:06 PM
“I felt like a butterfly”: Niko Flowers on reclaiming life with HIV
July 23 2025 12:22 PM
Dancer. Healer. Survivor. DéShaun Armbrister is all of the above
July 02 2025 8:23 PM
BREAKING: Supreme Court rules to save free access to preventive care, including PrEP
June 27 2025 10:32 AM
1985: the year the AIDS crisis finally broke through the silence
June 26 2025 11:24 AM
VIDEO: A man living with HIV discusses his journey to fatherhood
June 10 2025 4:58 PM
Trump admin guts $258 million in funding for HIV vaccine research
June 03 2025 3:47 PM
Trending stories
Recommended Stories for You



































































